Solvazinc
Phase 1Small molecule
Solvazinc is one of 13 small molecule programs targeting Myofascial Pain Syndrome. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Myofascial Pain Syndrome
#DrugCompanyPhaseTrials
1Lioresal
NovartisApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Xylocaine
CCitius Pharmaceuticals, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 2
Botox
RRevance Therapeutics, Inc.
Preclinical
Marcaine
IInnocoll
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Myofascial Pain Syndrome1 trial
Botulinum Toxin A in Patients With Myofascial Pain Syndrome With and Without Zinc Supplementation
Unknown status·—·Phase 1·NCT05605886·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Solvazinc. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCairo University